Blog

Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab

Mark Tyson/X

May 25, 2025, 05:51

Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab

Mark Tyson, Associate Professor of Urology at Mayo Clinic in Arizona, posted on X:

“In SWOG 1605, utDNA (UroAmp) predicted response to Atezo in BCG-u bladder cancer. Baseline and 3 month positivity linked to lower CR and EFS.

A step toward biomarkers-driven bladder sparing care.”

Title: Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer.

Authors: Marie-Pier St-Laurent, Parminder Singh, David J. McConkey, M. Scott Lucia, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson Jr, Joshua J. Meeks, Vincent M. Caruso, Ceressa T. Ward, Brian C. Mazzarella, Kevin G. Phillips, Vincent T. Bicocca, Trevor G. Levin, Seth P. Lerner, Peter C. Black

Read The Full Article at European Urology.

Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Blog

OncoDaily

Blog

Mark Tyson: Urine Tumor DNA Stratifies Recurrence Risk in BCG-Unresponsive NMIBC Treated with Atezolizumab

“In SWOG 1605, utDNA (UroAmp) predicted response to Atezo in BCG-u bladder cancer. Baseline and 3 month positivity linked to lower CR and EFS.

A step toward biomarkers-driven bladder sparing care.”